Navigation Links
United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
Date:10/11/2011

SILVER SPRING, Md., Oct. 11, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) (the "Company") today announced that it intends to offer, subject to market and other conditions, $210 million aggregate principal amount of convertible senior notes due 2016 to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").  The Company also expects to grant to the initial purchaser of the notes an option to purchase up to an additional $40 million aggregate principal amount of notes, solely to cover over-allotments, if any.  The interest rate, conversion price and other terms of the notes will be determined at the time of pricing of the offering.

In order to reduce the potential dilution of the Company's common stock upon future conversion of the notes, the Company expects to enter into a convertible note hedge transaction with a financial institution that is an affiliate of the initial purchaser of the notes.  The Company also expects to enter into a separate warrant transaction with the same counterparty.

Using the proceeds to the Company from the warrant transaction and the balance of the net proceeds of the offering after purchasing the convertible note hedge, together with cash on hand, the Company intends to repurchase a variable number of shares of its common stock for up to approximately $212 million, pursuant to an accelerated share repurchase agreement to be entered into with an affiliate of the initial purchaser.  The accelerated share repurchase will be part of a broader share repurchase program authorized by the Company's board of directors, for up to $300 million in the Company's common stock.

The Company has been advised that, in connection with hedging the convertible note hedge, warrant and accelerated share repurchase transactions described above,
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
2. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
3. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
4. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
5. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
6. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
7. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
8. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
9. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
10. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
11. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... The global oligonucleotide synthesis market is ... $1,070.7 million in 2014, growing at a CAGR ... oligonucleotide synthesis market is categorized on the basis ... geography. The synthesized oligonucleotides segment is expected to ... synthesis market during the forecast period, owing to ...
(Date:8/31/2014)... Wockhardt Limited today announces a major boost ... when two of its drugs, WCK 771 and WCK ... status from U.S. Food & Drug Administration (FDA).  QIDP ... which have a high degree of unmet need in ... Control (a top U.S. government health and safety body). ...
(Date:8/31/2014)... 31, 2014 2014 Market ... a professional and in-depth research report on ... Polyacrylamide information, including Polyacrylamide definition, classification, application, ... industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 The ... a professional and in-depth study on the current ... Global and China. , The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ...
Breaking Biology Technology:9.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3
... Summary: Genmab Announced Today it has Amended the Ongoing HuMax-CD4, ... Received an Orphan Drug ... COPENHAGEN, Denmark, October 11 Genmab A/S,(OMX: GEN) announced ... of HuMax-CD4(R) (zanolimumab) to treat refractory cutaneous T-cell,lymphoma (CTCL) patients. ...
... 10 The National,Institutes of Allergy and Infectious ... Bavarian Nordic to include the initiation of,a larger ... vaccine, in persons diagnosed with atopic dermatitis. The ... and has a value of,US$15 million, with the ...
... 10 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... and Chief Financial Officer, is,scheduled to present a ... Tuesday, November 13, 2007 at 11:00 a.m. (Eastern ... To access the live audio broadcast or ...
Cached Biology Technology:Genmab Amends HuMax-CD4 Pivotal Study in CTCL 2Genmab Amends HuMax-CD4 Pivotal Study in CTCL 3Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 3Monogram Biosciences to Present at the JMP Securities Healthcare Conference 2
(Date:8/29/2014)... release is available in German . ... players in the natural nitrogen cycle on Earth and ... bacteria were thought to depend on nitrite as their ... by Holger Daims, a microbiologist at the University of ... hydrogen as an alternative source of energy. The oxidation ...
(Date:8/29/2014)... USA - The rise of the Tibetan plateau -- ... -- is important for both its profound effect on ... study published in GSA Bulletin , Katharine Huntington ... isotope thermometry -- using modern and fossil snail shells ... in southwestern Tibet. , Views range widely on ...
(Date:8/28/2014)... German . The ... a striking pattern of blue stripes alternating with golden stripes. ... and yellow cells emerge during growth in the skin of ... to compose the characteristic colour pattern. ,While it ... to form proper stripes, the embryonic origin of the pigment ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... approved to treat multiple sclerosis may also hold promise for ... that often leads to heart failure, researchers at the University ... findings are published in the July 16 issue of ... thickening of the heart muscle that shrinks the interior ...
... in an international study which has revealed the genetic secrets ... the most hostile environments on earth. The ground tit ... largest high-altitude land mass in the world. This study has ... how it copes with the extreme living conditions of this ...
... avian H7N9 influenza that emerged in China this year have ... the infection, but testing for antiviral resistance can give misleading ... The authors of a study published in mBio , ... characterized viruses taken from the first person known to be ...
Cached Biology News:MS drug shows promise for preventing heart failure 2Genetic secrets of the world's toughest little bird 2Genetic secrets of the world's toughest little bird 3H7N9 influenza strain resistant to antivirals, but tests fail to identify resistance 2H7N9 influenza strain resistant to antivirals, but tests fail to identify resistance 3
Transfection Buffer A & B Set 5 ml each...
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
... Anti-phospho-Hck [pTyr 209/ pSer 211 ] ... solution in Dulbecco's phosphate buffered saline (without Mg ... with 1.0 mg/ml BSA (IgG and protease free) ... derived from the region of mouse Hck that ...
Biology Products: